The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...

Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...